P-97 Updated results of HGCSG1603: A phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer

M Nakamura,Y Kawamoto,S Yuki,K Sawada,O Muto,S Sogabe,Y Shindo,A Ishiguro,A Sato,Y Tsuji,M Dazai,H Okuda,T Sasaki,K Harada,H Nakatsumi,K Iuchi,Y Sakata,Y Komatsu

doi:10.1016/j.annonc.2021.05.152

Abstract

Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. We previously reported the efficacy and safety of RAM plus irinotecan (IRI) combination therapy in the second-line treatment for advanced gastric cancer (AGC). This is an updated analysis of the HGCSG1603 trial.

Full Text